Published in Intensive Care Med on September 18, 2008
Patients with preexisting psychiatric disorders admitted to ICU: a descriptive and retrospective cohort study. Ann Intensive Care (2017) 0.75
Substance dependence and psychiatric disorders are related to outcomes in a mixed ICU population. Intensive Care Med (2008) 1.48
Intravascular Complications of Central Venous Catheterization by Insertion Site. N Engl J Med (2015) 7.02
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet (2008) 6.24
Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry (2005) 2.58
Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication. Pharmacopsychiatry (2004) 1.82
Impaired plasma B-type natriuretic peptide clearance in human septic shock. Crit Care Med (2008) 1.59
Osteoporosis in patients with schizophrenia. Am J Psychiatry (2005) 1.58
Disturbances of electrolytes and blood chemistry in acute alcohol intoxication. Wien Klin Wochenschr (2005) 1.47
Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenia patient. J Clin Psychiatry (2003) 1.46
Attitudes towards medication in patients with schizophrenia. Acta Psychiatr Scand (2006) 1.44
Value of lactic acidosis in the assessment of the severity of acute cyanide poisoning. Crit Care Med (2002) 1.42
Should all out-of-hospital cardiac arrest patients presenting with cardiogenic shock be treated with therapeutic hypothermia? Crit Care Med (2013) 1.40
Maintaining lithium elimination is at least as important as early gastrointestinal decontamination in acute-on-chronic poisonings. Clin Toxicol (Phila) (2013) 1.39
Is early implementation of extracorporeal life support in severely colchicine-poisoned patients lifesaving? Definitive evidence is still lacking. Intensive Care Med (2013) 1.38
Thallium poisoning: one additional and unexpected risk of heroin abuse. Clin Toxicol (Phila) (2012) 1.21
Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry (2012) 1.20
Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry (2012) 1.20
Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry (2004) 1.13
Endovascular hypothermia for heat stroke: a case report. Intensive Care Med (2003) 1.12
Brain activation patterns during a selective attention test--a functional MRI study in healthy volunteers and unmedicated patients during an acute episode of schizophrenia. Psychiatry Res (2006) 1.11
Normative data for functional assessment of cancer therapy--general scale and its use for the interpretation of quality of life scores in cancer survivors. Acta Oncol (2004) 1.10
Gender differences in regional cerebral activity during the perception of emotion: a functional MRI study. Neuroimage (2006) 1.08
Olfactory functions and volumetric measures of orbitofrontal and limbic regions in schizophrenia. Schizophr Res (2005) 1.08
Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res (2005) 1.07
[Letter on the article "relation between creatinine level and kalaemia in patients with digitalis poisoning"]. Presse Med (2012) 1.07
A funny patient. J R Soc Med (2007) 1.06
Cognitive remediation therapy during treatment for alcohol dependence. J Stud Alcohol Drugs (2012) 1.06
Patient outcomes in schizophrenia II: the impact of cognition. Eur Psychiatry (2005) 1.05
Attitudes of patients with schizophrenia toward placebo-controlled clinical trials. J Clin Psychiatry (2003) 1.04
Various bilateral olfactory deficits in male patients with schizophrenia. Schizophr Bull (2005) 1.04
Hydroxocobalamin for severe acute cyanide poisoning by ingestion or inhalation. Am J Emerg Med (2007) 1.03
The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol. Clin Toxicol (Phila) (2012) 1.02
Fatigue in ovarian carcinoma patients: a neglected issue? Cancer (2003) 1.02
Dietary poisoning with Veratrum album--a report of two cases. Wien Klin Wochenschr (2005) 1.02
Brain activation patterns during a selective attention test-a functional MRI study in healthy volunteers and patients with schizophrenia. Psychiatry Res (2003) 1.01
Reduced olfactory sensitivity, discrimination, and identification in patients with alcohol dependence. Alcohol Clin Exp Res (2003) 1.01
An FMRI study of episodic encoding and recognition of words in patients with schizophrenia in remission. Am J Psychiatry (2003) 1.01
Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res (2009) 1.00
Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. Eur Arch Psychiatry Clin Neurosci (2005) 0.97
Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res (2013) 0.97
Dichlorvos, chlorpyrifos oxon and Aldicarb adducts of butyrylcholinesterase, detected by mass spectrometry in human plasma following deliberate overdose. J Appl Toxicol (2010) 0.95
Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it? Int J Neuropsychopharmacol (2012) 0.95
No evidence for an association between serum cholesterol and the course of depression and suicidality. Psychiatry Res (2004) 0.95
Catheter dysfunction and dialysis performance according to vascular access among 736 critically ill adults requiring renal replacement therapy: a randomized controlled study. Crit Care Med (2010) 0.94
Language lateralization in unmedicated patients during an acute episode of schizophrenia: a functional MRI study. Psychiatry Res (2006) 0.94
Low bone mineral density and impaired bone metabolism in young alcoholic patients without liver cirrhosis: a cross-sectional study. Alcohol Clin Exp Res (2008) 0.94
Comparison of image quality and radiation dose of different pulmonary CTA protocols on a 128-slice CT: high-pitch dual source CT, dual energy CT and conventional spiral CT. Eur Radiol (2011) 0.93
Detection of adduct on tyrosine 411 of albumin in humans poisoned by dichlorvos. Toxicol Sci (2010) 0.92
Carbofuran poisoning detected by mass spectrometry of butyrylcholinesterase adduct in human serum. J Appl Toxicol (2009) 0.92
Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry (2003) 0.92
Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective. CNS Drugs (2013) 0.92
Case 6-2004: severe burns from a nightclub fire. N Engl J Med (2004) 0.91
Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period. Schizophr Res (2005) 0.91
Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry (2002) 0.91
Longitudinal volumetric MRI study in first- and multiple-episode male schizophrenia patients. Psychiatry Res (2005) 0.91
Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol (2010) 0.90
Brain activation patterns during a verbal fluency test-a functional MRI study in healthy volunteers and patients with schizophrenia. Schizophr Res (2004) 0.90
Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood-brain barrier in mice. Crit Care Med (2012) 0.90
Drug Fever: a descriptive cohort study from the French national pharmacovigilance database. Drug Saf (2012) 0.89
The clinical relevance of percentage improvements on the PANSS score. Neuropsychopharmacology (2007) 0.89
Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry (2011) 0.88
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. Eur Neuropsychopharmacol (2012) 0.88
Scorpion envenomation. N Engl J Med (2014) 0.88
Neural correlates of episodic encoding and recognition of words in unmedicated patients during an acute episode of schizophrenia: a functional MRI study. Am J Psychiatry (2003) 0.87
Delayed immunosuppressive treatment in life-threatening paraquat ingestion: a case report. J Med Toxicol (2009) 0.86
Continuous renal replacement therapy may increase the risk of catheter infection. Clin J Am Soc Nephrol (2010) 0.86
Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects. Eur Psychiatry (2005) 0.85
Long-term survival and neurological outcome of patients who received recombinant tissue plasminogen activator during out-of-hospital cardiac arrest. Resuscitation (2004) 0.84
The interrelation of needs and quality of life in first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci (2011) 0.84
Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse? J Clin Psychopharmacol (2010) 0.84
Is elevated plasma lactate a useful marker in the evaluation of pure carbon monoxide poisoning? Intensive Care Med (2003) 0.84
Sibutramine in the treatment of antipsychotic-induced weight gain: a pilot study in patients with schizophrenia. Int Clin Psychopharmacol (2014) 0.83
Switching between second-generation antipsychotics: why and how? CNS Drugs (2005) 0.83
Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophr Res (2013) 0.82
Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia. Schizophr Res (2009) 0.82
Emerging drugs for schizophrenia. Expert Opin Emerg Drugs (2011) 0.82
Poor health behaviour and reduced quality of life of people treated with psychotropic drugs. Hum Psychopharmacol (2011) 0.82
Cognitive impairment in schizophrenia: clinical ratings are not a suitable alternative to neuropsychological testing. Schizophr Res (2007) 0.82
Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial. J Clin Psychopharmacol (2011) 0.81
The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia. Psychopharmacology (Berl) (2002) 0.81
Assessment of digoxin antibody use in patients with elevated serum digoxin following chronic or acute exposure. Intensive Care Med (2008) 0.80
Management of a risperidone-induced tardive Pisa syndrome: a case report. J Clin Psychopharmacol (2012) 0.80
Executive function and memory in relation to olfactory deficits in alcohol-dependent patients. Alcohol Clin Exp Res (2006) 0.80
Attitudes of patients with schizophrenia and depression to psychiatric research: a study in seven European countries. Soc Psychiatry Psychiatr Epidemiol (2010) 0.80
Cerebral output of cytokines in patients with pneumococcal meningitis. Crit Care Med (2005) 0.80
Insight: demographic differences and associations with one-year outcome in schizophrenia and schizoaffective disorder. Clin Schizophr Relat Psychoses (2010) 0.80
Chloroquine poisoning-associated inverted Tako-tsubo cardiomyopathy. Clin Toxicol (Phila) (2012) 0.80
Elevation of cardiac troponin I during non-exertional heat-related illnesses in the context of a heatwave. Crit Care (2010) 0.80
Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials. Curr Opin Psychiatry (2013) 0.80
Blood cocaine and metabolite pharmacokinetics after cardiac arrest in a body-packer case. Hum Exp Toxicol (2009) 0.80
Poisoning-related bowel infarction: characteristics and outcomes. Clin Toxicol (Phila) (2009) 0.79
Olfactory functioning in patients with alcohol dependence: impairments in odor judgements. Alcohol Alcohol (2004) 0.79
Swallowing disorders as a predictor of unsuccessful extubation: a clinical evaluation. Am J Crit Care (2008) 0.79
The smoker's paradox and the real risk of smoking. Eur J Epidemiol (2005) 0.79
Early changes of plasma lipids during treatment with atypical antipsychotics. Int Clin Psychopharmacol (2006) 0.79
Toxic doses of paraoxon alter the respiratory pattern without causing respiratory failure in rats. Toxicology (2006) 0.79
The effect of nabilone on neuropsychological functions related to driving ability: an extended case series. Hum Psychopharmacol (2005) 0.79
The soluble leptin receptor in olanzapine-induced weight gain: results from a prospective study. Schizophr Res (2005) 0.79
Association between antipsychotic-induced elevation of liver enzymes and weight gain: a prospective study. J Clin Psychopharmacol (2006) 0.79
Problematic drugs in elderly patients presenting to a European emergency room. Eur J Intern Med (2003) 0.79